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Chairs G. Gialdroni Grassi (Pavia, Ita&) 
J. Jardim (Sao Puolo, Brazil) 
Learning from each other international viewpoints 
of management 
Standard practice in North America 
L. Mandell (Hamilton, Canada) 
Standard practice in Japan 
S. Kohno (Nagasaki, Japan) 
Standard practice in Europe 
G. Huchon (Paris, France) 
Standard practice in Latin America 
G. Luna (Buenos Aires, Argentina) 
Contributions from the audience 
08.30 SYMPOSIUM 2 
Chairs L. Mandell (Hamilton, Canada) 
A. Torres Marti (Barcelona, Spain) 
Nosocomial and ventilator associated pneumonia: 
current controversies 
The bacteriology of ventilator associated pneumonia 
J. Chastre (Paris, France) 
Perspectives on monotherapy, combination and 
rotation 
H. Lode (Berlin, Germany) 
Mini-Debate: do invasive diagnostic procedures 
affect the outcome of VAP 
M. Niederman (New York, NY US.A.) vs. 
J. Y Fagon (Paris, France) 
Nosocomial pneumonia old and emerging concepts 
for prevention 
D. Craven (Boston, MA, 2IS.A.) 
14.45 PLENARY LECTURE 1 10.00 Coffee Break 
Chair R. Wise (Birmingham, UK.) 
Global issues: antibiotic usage, resistance 
emergence and control. Including resistance to 
new drugs 
D. Low (Toronto, Canada) 
15.30 Tea Break 
10.30 PLENARY LECTURE 3 
Chairs J. Garau (Barcelona, Spain) 
A. Mistretta (Catania, ZtaZy) 
Cost effective management of community 
RTIs: evidence-based realities vs. experience-based 
empiricism plus cost-efficacy considerations 
M. Niederman (New York, NY US.A.) 
16.00 SYMPOSIUM 1 
11.00 DEBATE 
Chairs L. Allegra (Milan, Italy) 
R. Wilson (London, UK.) 
AECB-1: basic concepts of a heterogeneous disease 
Bacteria from adherence to invasion: effects on 
disease progression 
Chairs T. File (Akron, OH, L%S.A.) 
I? Ball (F@, UK.) 
Treatment of RTI: a needfor change? 
Introduction: An environment for change? 
T. File (Akron, OH, U.S.A.) 
I? Ball (Fife, UK.) 
S. Hill (Birmingham, UK.) 
Standard versus new antibiotics: novel outcomes in 
clinical trial design 
R. Wilson (London, UK) 
Bacterial eradication, suppression, sequestration or 
dormancy? 
S. Sethi (Buffalo, NY US.A.) 
Does any of this matter?: a family practice view 
B. Holmes (Nottingham, UK.) 
Does any of this matter?: a managed care view 
J. Sbarbaro (Denver, CO, L!SA.) 
Primary care practice-a prescription for 
antimicrobial resistance? 
Debating the controversy of appropriate antibiotic 
prescribing 
(1) Evidence supporting the reservation of newer, 
more potent agents for severe infectios and 
treatment failures only 
J. Garau (Barcelona, Spain) 
(2) Resistance necessitates change 
T. File (Akron, OH, L%SA.) 
Open Discussion 
17.30 PLENARY LECTURE 2 (3) The real cost of antibiotic choices 
P. Davey (Fife, UK.) 
Chairs S. Kohno (Nagasaki, Japan) 
D. Bassetti (Genoa, Italy) 
Macro-aza-ketolides in RTI therapy: 
antibacterial and anti-inflammatory effects 
H. Kobayashi (Tokyo, Japan) 
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Changing prescribing habits-are current 
initiatives working? 
(1) Have guidelines influenced outcomes/resistance 
E. Rubinstein (Tel-Hashomer, Israel) 
A.4 ABSTRACTS 
(2) The implementation and effects of changes in 
antibiotic consumption pattern 
0. Cars (Uppsala, Sweden) 
Proven strategies for change: behavioural models 
S. Johnson (West Kingston, m, L?S. A.) 
Defining the way forward-method and means 
T. File (Akron, OH, L!SA.) 
P. Ball (F@, UK.) 
12.30 Lunch 
February16,2000 
13.30 SYMPOSIUM 3 
Chairs Y. Niki (Kawasaki, Japan) 
I? Ball (Fe, L! K.) 
AECB-2: practical management 
New antibacterials for AECB: Japanese experience 
Y. Niki (Kawasaki, Japan) 
New antibacterials for AECB: Western experience 
V T. Andriole (New Haven, CT US. A.) 
Clinical applicability of pharmacodynamics in 
AECB 
J. Schentag (BuffuZo, NY; l% S. A.) 
Management options: reactive, cyclical pulse, 
sequential, long-term 
R. Wilson (London, UK.) 
Management options: non antibacterial agents 






Chairs N. Hoiby (Copenhagen, Denmark) 
H. Kobayashi (Tokyo, Japan) 
Cysticjibrosis, bronchiectasis and diffuse pan- 
bronchiolitis 
Inter-relationships with diffuse pan-bronchiolitis 
J.-I. Kadota (Nagasaki, Japan) 
Changing microbiology: impact on outcomes and 
infection control 
N. Hoiby (Copenhagen, Denmark) 
Gene therapy 
P Squiban (Strasbourg, France) 
Management. of the older surviving patient 
E. Pozzi (Turin, Italy) 
PLENARY LECTURE 4 
Chair A. Torres Marti (Barcelona, Spain) 
New treatment options in community acquired 
pneumonia 
D. Campbell (Shreveport, LA, US. A.) 
February17,2000 
08.30 SYMPOSIUM 5 
Chairs G. C. Schito (Genoa, Italy) 
H. Lode (Berlin, Germany) 
Community acquiredpneumonia-1: management 
turning points 
Spread and implications of DRSP 
K. Klugman (Johannesburg, South Africa) 
Do current diagnostic techniques allow directed 
therapy? 
T. File (Akron, OH, US.A.) 
Can PCR and molecular techniques replace the 
microbiologist? 
J. Verhoef (Utrecht, The Netherlands) 
Optimal IV-oral switch therapy 
J. Ramirez (Louisville, KI: US. A.) 
Severe CAP: changing aetiology, patients and 
therapy 
A. Torres Marti (Barcelona, Spain) 
10.30 Coffee Break 
11.00 SYMPOSIUM 6 
Chairs R. Wise (Birmingham, UK.) 
E. Rubinstein (Tel-Hashomer, Israel) 
Community acquired pneumonia-2: spectfic 
approaches 
Influenza: progress in prophylaxis and treatment 
F! Gross (Ridgewood, NJ L!S. A.) 
Chlamydophila pneumoniae: how many roles 
F. Blasi (Milan, Ztuly) 
Fluoroquinolone pharmacodynamics: a paradigm 
for the future? 
S. Zinner (Cambridge, MA, US. A.) 
Will fluoroquinolones succeed when other agents 
fail? 
E. Rubinstein (Tel-Hashomer, Israel) 
12.30 Lunch 
13.30 PLENARY LECTURE 5 
Chair F. Paradisi (Florence, ZtuZy) 
Adverse reactions qf respiratory antibacterials 
Risk benefit and regulatory issues 
P. Ball (F$z, UK.) 
14.00 ROUND TABLE 
Chairs C. Grassi (&via, ZtaZy) 
R. Wilson (London. UK.) 
Harmonizing AECB guidelines ’ 
Guidelines compared: 
ERS Task Force (1998) 
M. Woodhead (Manchester, UK.) 
ATS view 
Canadian view 
M. Balter (Toronto, Canada) 
Latin America 
J. Jardlm (Suo Paolo, Brazil) 
Japanese Experience 
Y. Niki (Kawasaki, Japan) 
Discussion 
Have guidelines impacted on clinical practice? 
R. Grossman (Toronto, Canada) 
Severity predictors: short and long-term 
L. Allegra (Mihzn, It&) 
Can severity be classified? 
M. Miravitiles (Barcelona, Spain) 
Discussion 
Treatment decision factors: clinical or 
bacteriological 
J. C. Pechere (Geneva, Switzerland) 
Assessment of outcomes 
F? W. Jones (London UK.) 
